retatrutide triple agonist gip glp-1 glucagon ly3437943 mechanism Beyond GLP -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based Eli Lilly just announced striking
Pay in 4 interest-free payments of $7.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21

01053-X/asset/68ad1d8b-bb7e-4ca0-8f89-99384d885ca3/main.assets/gr2.jpg)

























